THE COMBINATION OF EXTERNAL RADIATION THERAPY WITH HIGH DOSE RATE BRAHYTERAPY BOOST FOR PROSTATE CANCER: A COMPARATIVE CHARACTERISTIC OF TWO FRACTION MODES

The purpose of the study was to analyze treatment outcomes in prostate cancer patients, who received external radiotherapy combined with high dose rate (HDR) 198Ir brachytherapy boost of 10 Gy in 2 fractions or 15 Gy in 1 fraction.

Material and methods. Between July 2012 and June 2017, 98 patients with prostate cancer received radiation therapy at N.N. Petrov National Medical Research Center of Oncology (St-Petersburg, Russia). Intensitymodulated radiation therapy (IMRT) at a total dose of 46–50 Gy was delivered to the prostate, seminal vesicles and regional lymph outflow areas (RTOG, 2009). The patients were then divided into 2 groups. Group I patients (81 patients, 82.7 %) received HDR brachytherpy boost of 10 Gy in 2 fractions, Group II patients (17 patients, 17.3 %) received HDR brachytherpy boost of 15 Gy in 1 fraction. Inclusion criteria were: high or extremely high risk of relapse according to NCCN (2010), no evidence of distant metastases and no evidence of pronounced urinary tract disorders (residual urine volume less than 50 ml, IPSS less than 17 points, maximum urination rate ≥10 ml / sec). Assessment of radiation-induced complications (toxicity) was carried out in accordance with generally accepted RTOG / EORTC (1995) criteria and taking into account the terminological recommendations of CTCAE v 4.0 (2009).

Results. The median follow-up time was 39.2 [30.7; 48.7] (20.3–69.8) months in Group I and 37.0 [30.9; 47.9] (23.7–50.7) months in Group II. The 3-year disease-free survival rate in the study groups regardless of the boost was 77.1 % (75.9 % in Group I and 77.8 % in group II, p=0.7). The 3-year disease-free survival rates in patients with high and extremely high risk regardless of the radiotherapy regimen were 88.6 % and 70.8 %, respectively (р=0.04). Genitourinary early radiation toxicity and rectal intestinal early radiation toxicity of grade 3 were observed in 13.5% and 12.3 % of Group I patients and in 17.6 and 5.9 % of Group II patients. The most significant late complications were the formation of urethral stricture (1 patient of group I) and postradiation rectal stenosis (1 patient of group II). Evaluation of the level of erectile function in both groups showed a significant decrease in satisfaction with the quality of sexual life, which, apparently, can be explained not only by radiation damage to the structures responsible for hemodynamics of the penis, but also by castration syndrome due to prolonged hormonal deprivation in the vast majority of patients.

Conclusion. The combination of external beam radiation therapy with HDR brachytherapy boost is an effective method of radical treatment of prostate cancer patients with high and extremely high risk of recurrence.

1. Mohler J., Bahnson R.R., Boston B., Busby J.E., D'Amico A., Eastham J.A., Enke C.A., George D., Horwitz E.M., Huben R.P., Kantoff P., Kawachi M., Kuettel M., Lange P.H., Macvicar G., Plimack E.R., PowSang J.M., Roach M. 3rd, Rohren E., Roth B.J., Shrieve D.C., Smith M.R., Srinivas S., Twardowski P., Walsh P.C. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010 Feb; 8(2): 162–200. doi: 10.6004/jnccn.2010.0012.

2. Novikov S.N., Kanaev S.V., Novikov R.V., Iliin N.D., Gotovchikova M.Yu. HDR brachytherapy for prostate cancer in real time using 192‑Ir (features of dosimetric planning). Problems in Oncology. 2015; 61(1): 130–6. (in Russian).

3. Novikov S.N., Kanaev S.V., Novikov R.V., Iliin N.D., Gotovchikova M.Yu., Girshovich M.M. Clinical experience of using brachytherapy with high dose rate sources for monotherapy in prostate cancer patients. Problems in Oncology. 2018; 64(3): 366–73. (in Russian).

4. Lawton C.A., Michalski J., El-Naqa I., Buyyounouski M.K., Lee W.R., Menard C., O'Meara E., Rosenthal S.A., Ritter M., Seider M. RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high‑risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009 Jun; 74 (2): 383–7. doi: 10.1016/j.ijrobp.2008.08.002.

5. Hoskin P.J., Colombo A., Henry A., Niehoff P., Paulsen Hellebust T., Siebert F.A., Kovacs G. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: аn update. Radiother Oncol. 2013 Jun; 107 (3): 325–32. doi: 10.1016/j.radonc.2013.05.002.

6. Roach M. 3rd, Hanks G., Thames H. Jr., Schellhammer P., Shipley W.U., Sokol G.H., Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG‑ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006 Jul; 65(4): 965–74. doi: 10.1016/j.ijrobp.2006.04.029.

7. Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995 Mar; 31(5): 1341–6. doi: 10.1016/0360‑3016(95)00060‑C.

8. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. May 28, 2009.

9. Roach M.3rd, Marquez C., Yuo H.S., Narayan P., Coleman L., Nseyo U.O., Navvab Z., Carroll P.R. Predicting the risk of lymph node involvement using the pre‑treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994 Jan; 28(1): 33–7. doi: 10.1016/0360‑3016(94)90138‑4.

10. Briganti A., Larcher A., Abdollah F., Capitanio U., Gallina A., Suardi N., Bianchi M., Sun M., Freschi M., Salonia A., Karakiewicz P.I., Rigatti P., Montorsi F. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol. 2012 Mar; 61(3): 480–7. doi: 10.1016/j.eururo.2011.10.044.

11. Asbell S.O., Krall J.M., Pilepich M.V., Baerwald H., Sause W.T., Hanks G.E., Perez C.A. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77‑06. Int J Radiat Oncol Biol Phys. 1988 Dec; 15(6): 1307–16. doi: 10.1016/0360‑3016(88)90225‑8.

12. Zelefsky M.J., Whitmore W.F. Jr, Leibel S.A., Wallner K.E., Fuks Z. The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. Int J Radiat Oncol Biol Phys. 1994 Jan; 28 (1): 7–16. doi: 10.1016/0360‑3016‑(94)90135‑X.

13. Pommier P., Chabaud S., Lagrange J.L., Richaud P., Lesaunier F., Le Prise E., Wagner J.P., Hay M.H., Beckendorf V., Suchaud J.P., Pabot du Chatelard P.M., Bernier V., Voirin N., Perol D., Carrie C. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG‑01. J Clin Oncol. 2007 Dec; 25 (34): 5366–73. doi: 10.1200/JCO.2006.10.5171.

14. Spratt D.E., Soni P.D., McLaughlin P.W., Merrick G.S., Stock R.G., Blasko J.C., Zelefsky M.J. The American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high‑risk prostate cancer. Brachytherapy. 2017 Jan‑Feb; 16 (1): 1–12. doi: 10.1016/j.brachy.2016.09.006.

15. Helou J., D'Alimonte L., Loblaw A., Chung H., Cheung P., Szumacher E., Danjoux C., Ravi A., Deabreu A., Zhang L., Morton G. High dose‑rate brachytherapy boost for intermediate risk prostate cancer: Longterm outcomes of two different treatment schedules and early biochemical predictors of success. Radiother Oncol. 2015 Apr; 115 (1): 84–9. doi: 10.1016/j.radonc.2015.02.023.

16. Lauche O., Delouya G., Taussky D., Menard C., Béliveau-Nadeau D., Hervieux Y., Larouche R., Barkati M. Single‑fraction high‑dose‑rate brachytherapy using real‑time transrectal ultrasound based planning in combination with external beam radiotherapy for prostate cancer: dosimetrics and early clinical results. J Contemp Brachytherapy. 2016 Apr; 8 (2): 104–9. doi: 10.5114/jcb.2016.59216.

17. Morton G.C. High‑dose‑rate brachytherapy boost for prostate cancer: rationale and technique. J Contemp Brachyther. 2014 Oct; 6 (3): 323–30. doi: 10.5114/jcb.2014.45759.

18. De Bari B., Daidone A., Alongi F. Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature. Crit Rev Oncol Hematol. 2015 Jun; 94(3): 360–70. doi: 10.1016/j.critrevonc.2015.02.003.

19. Spratt D.E., Zumsteg Z.S., Ghadjar P., Kollmeier M.A., Pei X., Cohen G., Polkinghorn W., Yamada Y., Zelefsky M.J. Comparison of high‑dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate‑risk prostate cancer. BJU Int. 2014 Sep; 114 (3): 360–7. doi: 10.1111/bju.12514.

20. Liss A.L., Abu-Isa E.I., Jawad M.S., Feng F.Y., Vance S.M., Winfield R.J., Narayana V., Sandler H.M., McLaughlin P.W., Hamstra D.A. Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: the impact of Gleason pattern 5. Brachytherapy. 2015 Jul‑Aug; 14(4): 502–10. doi: 10.1016/j.brachy.2015.02.389.

21. Kishan A.U., Shaikh T., Wang P.C., Reiter R.E., Said J., Raghavan G., Nickols N.G., Aronson W.J., Sadeghi A., Kamrava M., Demanes D.J., Steinberg M.L., Horwitz E.M., Kupelian P.A., King C.R. Clinical outcomes for patients with Gleason score 9‑10 рrostate adenocarcinoma treated with radiotherapy or radical prostatectomy: a multiinstitutional comparative analysis. Eur Urol. 2017 May; 71(5): 766–773. doi: 10.1016/j.eururo.2016.06.046.

22. Sathya J.R., Davis I.R., Julian J.A., Guo Q., Daya D., Dayes I.S., Lukka H.R., Levine M. Randomized trial comparing iridium implant plus external‑beam radiation therapy with external‑beam radiation therapy alone in node‑negative locally advanced cancer of the prostate. J Clin Oncol. 2005 Feb; 23(6): 1192–9. doi: 10.1200/JCO.2005.06.154.

23. Hoskin P.J., Rojas A.M., Bownes P.J., Lowe G.J., Ostler P.J., Bryant L. Randomised trial of external beam radiotherapy alone or combined with high‑dose‑rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012 May; 103(2): 217–22. doi: 10.1016/j.radonc.2012.01.007.

24. Morris W.J., Tyldesley S., Rodda S., Halperin R., Pai H., McKenzie M., Duncan G., Morton G., Hamm J., Murray N. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE‑RT Trial): an analysis of survival endpoints for a randomized trial comparing a low‑dose‑rate brachytherapy boost to a dose‑escalated external beam boost for high‑ and intermediate‑risk prostate сancer. Int J Radiat Oncol Biol Phys. 2017 Jun; 98(2): 275–285. doi: 10.1016/j.ijrobp.2016.11.026.

25. Marshall R.A., Buckstein M., Stone N.N., Stock R. Treatment outcomes and morbidity following definitive brachytherapy with or without external beam radiation for the treatment of localized prostate cancer: 20‑year experience at Mount Sinai Medical Center. Urol Oncol. 2014 Jan; 32(1): 38.e1–7. doi: 10.1016/j.urolonc.2013.03.004